Abstract
Purpose: Disease caused by Bordetella pertussis is increasingly being identified among older children and adults in immunized populations, indicating a waning of the vaccine-induced immunity. These findings suggest the need for booster immunization of older children and adults. Modern acellular reduced-antigen-content vaccines have been developed, which can be given as a booster in individuals more than 4 years of age. This study was to assess the immunogenicity and reactogenicity of Boostrix™, GlaxoSmithKline Biologicals' reduced-antigen-content diphtheria-tetanus acellular pertussis (dTpa) vaccine, when administered as a booster in healthy subjects previously primed with DTP vaccine. Methods: Healthy Taiwanese children and adolescents aged 6-8 years and 15-20 years, previously primed with DTP vaccine, were enrolled. All received one dose of Boostrix™. Two blood samples were taken from each of them, one before vaccination and one at 1 month after vaccination. Serum antibodies to diphtheria and tetanus toxoids and immunoglobulin G (IgG) antibodies against the pertussis components PT, FHA and PRN were measured by enzyme-linked immunosorbent assay (ELISA) technique. Adverse reactions following vaccination were recorded. Results: A total of 180 subjects were recruited. The vaccine response rates to the pertussis antigens ranged between 89.0-100%. There were no serious adverse events reported during the study period. Conclusions: The results of this study suggest that Boostrix™ may be safely and effectively administered as a booster dose to children previously primed with DTP vaccine.
| Original language | English |
|---|---|
| Journal | Journal of Adolescent Health |
| Volume | 37 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Dec 2005 |
| Externally published | Yes |
Fingerprint
Keywords
- Adolescents
- Booster vaccination
- Bordetella pertussis
- Reduced-antigen-content dTpa vaccine
- Taiwan
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
Cite this
Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine in healthy Taiwanese children and adolescents. / Huang, Li Min; Chang, Luan Yin; Tang, Haiwen; Bock, Hans L.; Lu, Chun Yi; Huang, Fu Yuan; Lin, Tzou Yien; Lee, Chin Yun.
In: Journal of Adolescent Health, Vol. 37, No. 6, 12.2005.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine in healthy Taiwanese children and adolescents
AU - Huang, Li Min
AU - Chang, Luan Yin
AU - Tang, Haiwen
AU - Bock, Hans L.
AU - Lu, Chun Yi
AU - Huang, Fu Yuan
AU - Lin, Tzou Yien
AU - Lee, Chin Yun
PY - 2005/12
Y1 - 2005/12
N2 - Purpose: Disease caused by Bordetella pertussis is increasingly being identified among older children and adults in immunized populations, indicating a waning of the vaccine-induced immunity. These findings suggest the need for booster immunization of older children and adults. Modern acellular reduced-antigen-content vaccines have been developed, which can be given as a booster in individuals more than 4 years of age. This study was to assess the immunogenicity and reactogenicity of Boostrix™, GlaxoSmithKline Biologicals' reduced-antigen-content diphtheria-tetanus acellular pertussis (dTpa) vaccine, when administered as a booster in healthy subjects previously primed with DTP vaccine. Methods: Healthy Taiwanese children and adolescents aged 6-8 years and 15-20 years, previously primed with DTP vaccine, were enrolled. All received one dose of Boostrix™. Two blood samples were taken from each of them, one before vaccination and one at 1 month after vaccination. Serum antibodies to diphtheria and tetanus toxoids and immunoglobulin G (IgG) antibodies against the pertussis components PT, FHA and PRN were measured by enzyme-linked immunosorbent assay (ELISA) technique. Adverse reactions following vaccination were recorded. Results: A total of 180 subjects were recruited. The vaccine response rates to the pertussis antigens ranged between 89.0-100%. There were no serious adverse events reported during the study period. Conclusions: The results of this study suggest that Boostrix™ may be safely and effectively administered as a booster dose to children previously primed with DTP vaccine.
AB - Purpose: Disease caused by Bordetella pertussis is increasingly being identified among older children and adults in immunized populations, indicating a waning of the vaccine-induced immunity. These findings suggest the need for booster immunization of older children and adults. Modern acellular reduced-antigen-content vaccines have been developed, which can be given as a booster in individuals more than 4 years of age. This study was to assess the immunogenicity and reactogenicity of Boostrix™, GlaxoSmithKline Biologicals' reduced-antigen-content diphtheria-tetanus acellular pertussis (dTpa) vaccine, when administered as a booster in healthy subjects previously primed with DTP vaccine. Methods: Healthy Taiwanese children and adolescents aged 6-8 years and 15-20 years, previously primed with DTP vaccine, were enrolled. All received one dose of Boostrix™. Two blood samples were taken from each of them, one before vaccination and one at 1 month after vaccination. Serum antibodies to diphtheria and tetanus toxoids and immunoglobulin G (IgG) antibodies against the pertussis components PT, FHA and PRN were measured by enzyme-linked immunosorbent assay (ELISA) technique. Adverse reactions following vaccination were recorded. Results: A total of 180 subjects were recruited. The vaccine response rates to the pertussis antigens ranged between 89.0-100%. There were no serious adverse events reported during the study period. Conclusions: The results of this study suggest that Boostrix™ may be safely and effectively administered as a booster dose to children previously primed with DTP vaccine.
KW - Adolescents
KW - Booster vaccination
KW - Bordetella pertussis
KW - Reduced-antigen-content dTpa vaccine
KW - Taiwan
UR - http://www.scopus.com/inward/record.url?scp=27944432479&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=27944432479&partnerID=8YFLogxK
U2 - 10.1016/j.jadohealth.2005.08.009
DO - 10.1016/j.jadohealth.2005.08.009
M3 - Article
VL - 37
JO - Journal of Adolescent Health
JF - Journal of Adolescent Health
SN - 1054-139X
IS - 6
ER -